LONDON – Ablynx NV notched up its second deal of the week, announcing a collaboration with Merck Serono under which a dedicated discovery unit will be set up at Ablynx. Read More
Fibrocell Science Inc. went to the markets Thursday with an underwritten public offering of 11 million shares of common stock, priced at $4.10 apiece, seeking to generate $45.1 million. The price represented a hefty discount – 17.8 percent – to Wednesday’s closing price of $4.99 for Fibrocell’s shares (NYSE MKT:FCSC). Read More
A national track-and-trace system that would preempt the expanding patchwork of state regulations involving the drug supply chain may soon move a step closer to reality. Read More
It’s uninhibited. It’s degrading. It’s potentially a new class of drugs that does not just block disease proteins in cancer, but gets rid of them altogether. Read More
Scientists have discovered that the bone-derived hormone osteocalcin can cross both the placenta and the blood-brain barrier, and that it influences both prenatal brain development and adult brain function and behavior. Read More
• Agenus Inc., of Lexington, Mass., entered a nonexclusive license agreement with Vaxlogic LLC, a subsidiary of Boca-Raton, Fla.-based Pharmlogic LLC, for the use of QS-21 Stimulon adjuvant in the development of select addiction, allergy and respiratory disease vaccine candidates. Read More
• Chimerix Inc., of Durham, N.C., published results of a Phase II study of brincidofovir (CMX001) for cytomegalovirus (CMV) in hematopoietic cell transplant (HCT) recipients in the Sept. 26, 2013, issue of the New England Journal of Medicine. The drug has shown broad-spectrum antiviral activity against double-stranded DNA viruses, including CMV. Read More
• Ipsen SA, of Paris, said it will relocate to Cambridge, Mass., next year in a move that follows the company’s takeover this summer of Syntaxin Ltd. Read More
• Galectin Therapeutics Inc., of Norcross, Ga., was issued a U.S. Patent notice of issuance for 13/573,454, “Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.” Read More
• Eli Lilly and Co., of Indianapolis, disclosed positive patient-reported health outcomes from a Phase III trial of dulaglutide, an investigational, long-acting glucagon-like peptide 1 receptor agonist being studied as a once-weekly treatment for Type II diabetes. Read More
